Often rare diseases are chronic and life-threatening. Rare diseases can be single gene, multifactorial, chromosomal or non-genetic.
Rare Disease Diagnostics Market contains market size and forecasts of Rare Disease Diagnostics in Global, including the following market information:
- Global Rare Disease Diagnostics Market Revenue, 2017-2022, 2023-2028, ($ millions)
- Global top five companies in 2021 (%)
The global Rare Disease Diagnostics market was valued at 21130 million in 2021 and is projected to reach US$ 36100 million by 2028, at a CAGR of 8.0% during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Hematology Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Rare Disease Diagnostics include Retrophin, 3billion, 23andMe, QIAGEN, Illumina, PerkinElmer and Strand Life Sciences, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
We surveyed the Rare Disease Diagnostics companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Rare Disease Diagnostics Market, by Type, 2017-2022, 2023-2028 ($ millions)
Global Rare Disease Diagnostics Market Segment Percentages, by Type, 2021 (%)
Global Rare Disease Diagnostics Market, by Application, 2017-2022, 2023-2028 ($ millions)
Global Rare Disease Diagnostics Market Segment Percentages, by Application, 2021 (%)
- Hospital Laboratories
- Diagnostic Laboratories
- Genetic Testing Laboratories
- Cancer Research Laboratories
- Others
Global Rare Disease Diagnostics Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)
Global Rare Disease Diagnostics Market Segment Percentages, By Region and Country, 2021 (%)
- North America
- US
- Canada
- Mexico
- Europe
- Germany
- France
- U.K.
- Italy
- Russia
- Nordic Countries
- Benelux
- Rest of Europe
- Asia
- China
- Japan
- South Korea
- Southeast Asia
- India
- Rest of Asia
- South America
- Brazil
- Argentina
- Rest of South America
- Middle East & Africa
- Turkey
- Israel
- Saudi Arabia
- UAE
- Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
- Key companies Rare Disease Diagnostics revenues in global market, 2017-2022 (estimated), ($ millions)
- Key companies Rare Disease Diagnostics revenues share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
- Retrophin
- 3billion
- 23andMe
- QIAGEN
- Illumina
- PerkinElmer
- Strand Life Sciences
Industry Market Size
